Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
2.
Blood Cancer J ; 13(1): 28, 2023 02 17.
Artículo en Inglés | MEDLINE | ID: mdl-36797276

RESUMEN

Monoclonal gammopathy of undetermined significance (MGUS) is a benign hematological condition with the potential to progress to malignant conditions including multiple myeloma and Waldenstrom macroglobulinemia. Medications that modify progression risk have yet to be identified. To investigate, we leveraged machine-learning and electronic health record (EHR) data to screen for drug repurposing candidates. We extracted clinical and laboratory data from a manually curated MGUS database, containing 16,752 MGUS patients diagnosed from January 1, 2000 through December 31, 2021, prospectively maintained at Mayo Clinic. We merged this with comorbidity and medication data from the EHR. Medications were mapped to 21 drug classes of interest. The XGBoost module was then used to train a primary Cox survival model; sensitivity analyses were also performed limiting the study group to those with non-IgM MGUS and those with M-spikes >0.3 g/dl. The impact of explanatory features was quantified as hazard ratios after generating distributions using bootstrapping. Medication data were available for 12,253 patients; those without medications data were excluded. Our model achieved a good fit of the data with inverse probability of censoring weights concordance index of 0.883. The presence of multivitamins, immunosuppression, non-coronary NSAIDS, proton pump inhibitors, vitamin D supplementation, opioids, statins and beta-blockers were associated with significantly lower hazard ratio for MGUS progression in our primary model; multivitamins and non-coronary NSAIDs remained significant across both sensitivity analyses. This work could inform subsequent prospective studies, or similar studies in other disease states.


Asunto(s)
Gammopatía Monoclonal de Relevancia Indeterminada , Mieloma Múltiple , Paraproteinemias , Humanos , Gammopatía Monoclonal de Relevancia Indeterminada/diagnóstico , Gammopatía Monoclonal de Relevancia Indeterminada/tratamiento farmacológico , Gammopatía Monoclonal de Relevancia Indeterminada/complicaciones , Inteligencia Artificial , Estudios Prospectivos , Reposicionamiento de Medicamentos , Mieloma Múltiple/diagnóstico , Progresión de la Enfermedad
3.
Front Big Data ; 5: 833196, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35875593

RESUMEN

Electronic vaccine certificates (EVC) for COVID-19 vaccination are likely to become widespread. Blockchain (BC) is an electronic immutable distributed ledger and is one of the more common proposed EVC platform options. However, the principles of blockchain are not widely understood by public health and medical professionals. We attempt to describe, in an accessible style, how BC works and the potential benefits and drawbacks in its use for EVCs. Our assessment is BC technology is not well suited to be used for EVCs. Overall, blockchain technology is based on two key principles: the use of cryptography, and a distributed immutable ledger in the format of blockchains. While the use of cryptography can provide ease of sharing vaccination records while maintaining privacy, EVCs require some amount of contribution from a centralized authority to confirm vaccine status; this is partly because these authorities are responsible for the distribution and often the administration of the vaccine. Having the data distributed makes the role of a centralized authority less effective. We concluded there are alternative ways to use cryptography outside of a BC that allow a centralized authority to better participate, which seems necessary for an EVC platform to be of practical use.

4.
Artículo en Inglés | MEDLINE | ID: mdl-34977469

RESUMEN

OBJECTIVE: To investigate medication factors and patient characteristics associated with readmissions following alcohol-related hospitalizations. PATIENTS AND METHODS: Adult patients admitted from September 1, 2016, through August 31, 2019, who had an alcohol-related hospitalization were identified through electronic health records. Patient characteristics and medications of interest administered during hospitalization or prescribed at discharge were identified. Medications of interest included US Food and Drug Administration-approved medications for alcohol use disorder, benzodiazepines, barbiturates, gabapentin, opioids, and muscle relaxants. The primary outcome was to identify medications and patient factors associated with 30-day alcohol-related readmission. Secondary outcomes included medications and patient characteristics associated with multiple alcohol-related readmissions within a year from the index admission (ie, two or more readmissions) and factors associated with 30-day all-cause readmission. RESULTS: Characteristics of the 932 patients included in this study associated with a 30-day alcohol-related readmission included younger age, severity of alcohol withdrawal, history of psychiatric disorder, marital status, and the number of prior alcohol-related admission in the previous year. Benzodiazepine or barbiturate use during hospitalization or upon discharge was associated with 30-day alcohol-related readmission (P=.006). Gabapentin administration during hospitalization or upon discharge was not associated with 30-day alcohol-related readmission (P=.079). CONCLUSION: The findings reinforce current literature identifying patient-specific factors associated with 30-day readmissions. Gabapentin use was not associated with readmissions; however, there was an association with benzodiazepine/barbiturate use.

5.
Mayo Clin Proc Innov Qual Outcomes ; 6(3): 193-199, 2022 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-35517246

RESUMEN

Objective: To assess the generalizability of a clinical machine learning algorithm across multiple emergency departments (EDs). Patients and Methods: We obtained data on all ED visits at our health care system's largest ED from May 5, 2018, to December 31, 2019. We also obtained data from 3 satellite EDs and 1 distant-hub ED from May 1, 2018, to December 31, 2018. A gradient-boosted machine model was trained on pooled data from the included EDs. To prevent the effect of differing training set sizes, the data were randomly downsampled to match those of our smallest ED. A second model was trained on this downsampled, pooled data. The model's performance was compared using area under the receiver operating characteristic (AUC). Finally, site-specific models were trained and tested across all the sites, and the importance of features was examined to understand the reasons for differing generalizability. Results: The training data sets contained 1918-64,161 ED visits. The AUC for the pooled model ranged from 0.84 to 0.94 across the sites; the performance decreased slightly when Ns were downsampled to match those of our smallest ED site. When site-specific models were trained and tested across all the sites, the AUCs ranged more widely from 0.71 to 0.93. Within a single ED site, the performance of the 5 site-specific models was most variable for our largest and smallest EDs. Finally, when the importance of features was examined, several features were common to all site-specific models; however, the weight of these features differed. Conclusion: A machine learning model for predicting hospital admission from the ED will generalize fairly well within the health care system but will still have significant differences in AUC performance across sites because of site-specific factors.

6.
J Am Med Inform Assoc ; 28(9): 1977-1981, 2021 08 13.
Artículo en Inglés | MEDLINE | ID: mdl-34151986

RESUMEN

Hospital census prediction has well-described implications for efficient hospital resource utilization, and recent issues with hospital crowding due to CoVID-19 have emphasized the importance of this task. Our team has been leading an institutional effort to develop machine-learning models that can predict hospital census 12 hours into the future. We describe our efforts at developing accurate empirical models for this task. Ultimately, with limited resources and time, we were able to develop simple yet useful models for 12-hour census prediction and design a dashboard application to display this output to our hospital's decision-makers. Specifically, we found that linear models with ElasticNet regularization performed well for this task with relative 95% error of +/- 3.4% and that this work could be completed in approximately 7 months.


Asunto(s)
Censos , Hospitales , COVID-19 , Humanos , Aprendizaje Automático
7.
BMJ ; 373: n1087, 2021 05 12.
Artículo en Inglés | MEDLINE | ID: mdl-33980718

RESUMEN

OBJECTIVE: To estimate population health outcomes with delayed second dose versus standard schedule of SARS-CoV-2 mRNA vaccination. DESIGN: Simulation agent based modeling study. SETTING: Simulated population based on real world US county. PARTICIPANTS: The simulation included 100 000 agents, with a representative distribution of demographics and occupations. Networks of contacts were established to simulate potentially infectious interactions though occupation, household, and random interactions. INTERVENTIONS: Simulation of standard covid-19 vaccination versus delayed second dose vaccination prioritizing the first dose. The simulation runs were replicated 10 times. Sensitivity analyses included first dose vaccine efficacy of 50%, 60%, 70%, 80%, and 90% after day 12 post-vaccination; vaccination rate of 0.1%, 0.3%, and 1% of population per day; assuming the vaccine prevents only symptoms but not asymptomatic spread (that is, non-sterilizing vaccine); and an alternative vaccination strategy that implements delayed second dose for people under 65 years of age, but not until all those above this age have been vaccinated. MAIN OUTCOME MEASURES: Cumulative covid-19 mortality, cumulative SARS-CoV-2 infections, and cumulative hospital admissions due to covid-19 over 180 days. RESULTS: Over all simulation replications, the median cumulative mortality per 100 000 for standard dosing versus delayed second dose was 226 v 179, 233 v 207, and 235 v 236 for 90%, 80%, and 70% first dose efficacy, respectively. The delayed second dose strategy was optimal for vaccine efficacies at or above 80% and vaccination rates at or below 0.3% of the population per day, under both sterilizing and non-sterilizing vaccine assumptions, resulting in absolute cumulative mortality reductions between 26 and 47 per 100 000. The delayed second dose strategy for people under 65 performed consistently well under all vaccination rates tested. CONCLUSIONS: A delayed second dose vaccination strategy, at least for people aged under 65, could result in reduced cumulative mortality under certain conditions.


Asunto(s)
Vacunas contra la COVID-19/administración & dosificación , COVID-19/prevención & control , Salud Pública/estadística & datos numéricos , Tiempo de Tratamiento/estadística & datos numéricos , Vacuna nCoV-2019 mRNA-1273 , Adulto , Vacuna BNT162 , COVID-19/diagnóstico , COVID-19/epidemiología , COVID-19/virología , Vacunas contra la COVID-19/inmunología , Hospitalización , Humanos , Persona de Mediana Edad , Ocupaciones , Simulación de Paciente , SARS-CoV-2/genética , SARS-CoV-2/inmunología , Sensibilidad y Especificidad , Análisis de Sistemas , Resultado del Tratamiento , Vacunación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA